How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

558 results for

Malaria Chemoprophylaxis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate

steroids are allowed. Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab). Chronic use of antibiotics with antimalarial effects (e.g. tetracyclines for dermatologic patients, sulfa for recurrent urinary tract infections, etc.). History of malaria chemoprophylaxis within 60 days prior to vaccination. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Any history of anaphylaxis in relation (...) A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2016 Clinical Trials

122. Diagnosis and Treatment Malaria in Pregnancy

Diagnosis and Treatment Malaria in Pregnancy The diagnosis and treatment of malaria in pregnancy Green–top Guideline No. 54b April 2010RCOG Green-top Guideline No. 54b 2 of 29 © Royal College of Obstetricians and Gynaecologists The diagnosis and treatment of malaria in pregnancy This is the first edition of this guideline. 1. Purpose and scope The aim of this guideline is to provide clinicians with up-to-date, evidence-based information on the diagnosis and treatment of malaria in pregnancy (...) , in situations that are likely to be encountered in UK medical practice. For initial rapid assessment and management, see Appendix 1. 2. Background Malaria is the most important parasitic infection in humans and is the tropical disease most commonly imported into the UK, with approximately 1500 cases reported each year and rising, apart from 2008. 1 Approximately 75% of cases are caused by Plasmodium falciparum and there is an average of 5–15 deaths a year (mortality rate approximately 0.5–1.0%). 1

2010 Royal College of Obstetricians and Gynaecologists

123. Chemoprophylaxis of Homozygous Sicklers with Antimalarials and Long-acting Penicillin (Full text)

Chemoprophylaxis of Homozygous Sicklers with Antimalarials and Long-acting Penicillin 14305376 1996 12 01 2018 12 01 0007-1447 2 5453 1965 Jul 10 British medical journal Br Med J CHEMOPROPHYLAXIS OF HOMOZYGOUS SICKLERS WITH ANTIMALARIALS AND LONG-ACTING PENICILLIN. 86-8 WARLEY M A MA HAMILTON P J PJ MARSDEN P D PD BROWN R E RE MERSELIS J G JG WILKS N N eng Journal Article England Br Med J 0372673 0007-1447 0 Antimalarials 0 Delayed-Action Preparations 0 Ethylenediamines 0 Placebos 886U3H6UFF (...) Chloroquine C659VZ7P7T benzathine Q42T66VG0C Penicillin G RIT82F58GK Penicillin G Benzathine OM Adolescent Anemia Anemia, Sickle Cell Antimalarials Biomedical Research Chemoprevention Child Chloroquine Delayed-Action Preparations Drug Therapy Ethylenediamines Fingers Humans Infant Inflammation Malaria Penicillin G Penicillin G Benzathine Placebos Preventive Medicine Respiratory Tract Infections Statistics as Topic Toes Uganda ADOLESCENCE ANEMIA, SICKLE CELL CHILD CHLOROQUINE CLINICAL RESEARCH DELAYED

1965 British medical journal

124. Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

. Chronic use of antibiotics with antimalarial effects. History of malaria chemoprophylaxis within 60 days prior to vaccination. Any history of malaria. Planned travel to malaria endemic areas during the study period. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s) including latex. History of allergic disease or reactions likely to be exacerbated by chloroquine. History of psoriasis and porphyria, which may be exacerbated after chloroquine treatment (...) Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2013 Clinical Trials

125. Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force (Full text)

Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force The Australian Defence Force (ADF) has used mefloquine for malaria chemoprophylaxis since 1990. Mefloquine has been found to be a plausible cause of a chronic central nervous system toxicity syndrome and a confounding factor in the diagnosis of existing neuropsychiatric illnesses prevalent in the ADF such as posttraumatic stress disorder and traumatic brain injury

2015 Journal of parasitology research

126. Imported malaria including HIV and pregnant woman risk groups: overview of the case of a Spanish city 2004-2014. (Full text)

Imported malaria including HIV and pregnant woman risk groups: overview of the case of a Spanish city 2004-2014. Arrival of inmigrants from malaria endemic areas has led to a emergence of cases of this parasitic disease in Spain. The objective of this study was to analyse the high incidence rate of imported malaria in Fuenlabrada, a city in the south of Madrid, together with the frequent the lack of chemoprophylaxis, for the period between 2004 and 2014. Both pregnant women and HIV risk groups (...) have been considered.Retrospective descriptive study of laboratory-confirmed malaria at the Fuenlabrada University Hospital, in Madrid, during a 10-year period (2004-2014). These data were obtained reviewing medical histories of the cases. Relevant epidemiological, clinical and laboratory results were analysed, with focus on the following risk groups: pregnant women and individuals with HIV.A total of 185 cases were diagnosed (90.3 % Plasmodium falciparum). The annual incidence rate was 11.9

2015 Malaria journal

127. Cluster of Imported Vivax Malaria in Travelers Returning From Peru. (Full text)

species has increased during recent years. Travelers visiting this region should be counseled about the prevention of malaria and the options for chemoprophylaxis. © 2015 International Society of Travel Medicine. (...) Cluster of Imported Vivax Malaria in Travelers Returning From Peru. We report a cluster of imported vivax malaria in three of five Chilean travelers returning from Peru in March 2015. The cluster highlights the high risk of malaria in the Loreto region in northern Peru, which includes popular destinations for international nature and adventure tourism. According to local surveillance data, Plasmodium vivax is predominating, but Plasmodium falciparum is also present, and the incidence of both

2015 Journal of Travel Medicine

128. Recommendations for malaria prevention in moderate to low risk areas: travellers' choice and risk perception. (Full text)

Recommendations for malaria prevention in moderate to low risk areas: travellers' choice and risk perception. The considerable malaria decline in several countries challenges the strategy of chemoprophylaxis for travellers visiting moderate- to low-risk areas. An international consensus on the best strategy is lacking. It is essential to include travellers' opinions in the decision process. The preference of travellers regarding malaria prevention for moderate- to low-risk areas, related (...) to their risk perception, as well as the reasons for their choices were investigated.Prior to pre-travel consultation in the Travel Clinic, a self-administered questionnaire was given to travellers visiting moderate- to low-risk malaria areas. Four preventive options were proposed to the traveller, i.e., bite prevention only, chemoprophylaxis, stand-by emergency treatment alone, and stand-by emergency treatment with rapid diagnostic test. The information was accompanied by a risk scale for incidence

2015 Malaria journal

129. Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

of malaria ever, or use of malaria chemoprophylaxis within 60 days prior to vaccination Known exposure to malaria within the past 12 months or planned travel to malarious area during the study period Confirmed or suspected immunosuppressive or immunodeficient condition Family history of congenital or hereditary immunodeficiency History of allergic disease or reactions likely to be exacerbated by any component of the vaccine Chronic or active neurologic disease including seizures History of splenectomy (...) Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2012 Clinical Trials

130. Limited evidence on most effective prophylaxis for chloroquine-resistant malaria

Limited evidence on most effective prophylaxis for chloroquine-resistant malaria PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Limited evidence on most effective prophylaxis for chloroquine-resistant malaria Clinical question What is the most effective and safest prophylactic anti- malarial for non-immune adults and children travelling to regions with Plasmodium falciparum resistance (...) to chloroquine? Bottom line Atovaquone-proguanil and doxycycline were well tolerated by most travellers, and they were less likely than mefloquine to cause neuropsychiatric adverse events. Chloroquine-proguanil caused more gastrointestinal adverse events than other chemoprophylaxis. In other respects, the common unwanted effects of currently available drugs were similar. There was no evidence from head-to-head comparisons to support primaquine use as primary prophylaxis for travellers. The choice of whether

2011 Cochrane PEARLS

131. Unexpectedly long incubation period of Plasmodium vivax malaria, in the absence of chemoprophylaxis, in patients diagnosed outside the transmission area in Brazil. (Full text)

Unexpectedly long incubation period of Plasmodium vivax malaria, in the absence of chemoprophylaxis, in patients diagnosed outside the transmission area in Brazil. In 2010, Brazil recorded 3343,599 cases of malaria, with 99.6% of them concentrated in the Amazon region. Plasmodium vivax accounts for 86% of the cases circulating in the country. The extra-Amazonian region, where transmission does not occur, recorded about 566 cases imported from the Amazonian area in Brazil and South America, from (...) Central America, Asia and African countries. Prolonged incubation periods have been described for P. vivax malaria in temperate climates. The diversity in essential biological characteristics is traditionally considered as one possible explanation to the emergence of relapse in malaria and to the differences in the duration of the incubation period, which can also be explained by the use of chemoprophylaxis. Studying the reported cases of P. vivax malaria in Rio de Janeiro, where there is no vector

2011 Malaria journal

132. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. (Full text)

Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. In a number of malaria endemic regions, tourists and travellers face a declining risk of travel associated malaria, in part due to successful malaria control. Many millions of visitors to these regions are recommended, via national and international policy, to use chemoprophylaxis which has a well recognized morbidity profile. To evaluate whether current malaria chemo-prophylactic policy (...) for travellers is cost effective when adjusted for endemic transmission risk and duration of exposure. a framework, based on partial cost-benefit analysis was used.Using a three component model combining a probability component, a cost component and a malaria risk component, the study estimated health costs avoided through use of chemoprophylaxis and costs of disease prevention (including adverse events and pre-travel advice for visits to five popular high and low malaria endemic regions) and malaria

2011 Malaria journal

133. Malaria chemoprophylaxis recommendations for immigrants to Europe, visiting relatives and friends - a Delphi method study. (Full text)

Malaria chemoprophylaxis recommendations for immigrants to Europe, visiting relatives and friends - a Delphi method study. Numbers of travellers visiting friends and relatives (VFRs) from Europe to malaria endemic countries are increasing and include long-term and second generation immigrants, who represent the major burden of malaria cases imported back into Europe. Most recommendations for malaria chemoprophylaxis lack a solid evidence base, and often fail to address the cultural, social (...) experience of participants was rather diverse as was their selection of chemoprophylaxis regimen. A significant consensus was observed in only seven of 16 scenarios. The analysis revealed a wide variation in prescribing choices with preferences grouped by region of practice and increased prescribing seen in Northern Europe compared to Central Europe.Improving the evidence base on efficacy, adherence to chemoprophylaxis and risk of malaria and encouraging discussion among experts, using techniques

2011 Malaria journal

134. Review: malaria chemoprophylaxis for travelers to latin america. (Full text)

Review: malaria chemoprophylaxis for travelers to latin america. Because of recent declining malaria transmission in Latin America, some authorities have recommended against chemoprophylaxis for most travelers to this region. However, the predominant parasite species in Latin America, Plasmodium vivax, can form hypnozoites sequestered in the liver, causing malaria relapses. Additionally, new evidence shows the potential severity of vivax infections, warranting continued consideration (...) of prophylaxis for travel to Latin America. Individualized travel risk assessments are recommended and should consider travel locations, type, length, and season, as well as probability of itinerary changes. Travel recommendations might include no precautions, mosquito avoidance only, or mosquito avoidance and chemoprophylaxis. There are a range of good options for chemoprophylaxis in Latin America, including atovaquone-proguanil, doxycycline, mefloquine, and--in selected areas--chloroquine. Primaquine

2011 American Journal of Tropical Medicine & Hygiene

135. No, sleeping with a chicken probably won’t save you from Zika or malaria

of defense against malaria. “Measures to prevent mosquito bites include sleeping under long-lasting insecticidal nets, and using protective clothing and insect repellents. Depending on the malaria risk in the area to be visited, international travellers may also need to take preventive medication (chemoprophylaxis) prior to, during, and upon return from their travel.” NPR’s story included a comment from an outside source who thought the study was “pretty cool.” But I didn’t see any hint of skepticism (...) No, sleeping with a chicken probably won’t save you from Zika or malaria No, sleeping with a chicken probably won't save you from Zika or malaria - HealthNewsReview.org Note to our followers: Our nearly 13-year run of daily publication of new content on HealthNewsReview.org came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical

2016 HealthNewsReview

136. Review: provider practice and user behavior interventions to improve prompt and effective treatment of malaria: do we know what works?

), pre/post studies, time series, and post-only evaluations with a control group, were eligible. Studies of chemoprophylaxis, mass drug administration, traveller health or severe malaria (only) were excluded. Most of the user populations in the included studies were children aged under five years and (if relevant) their caretakers. The studies targeted diverse groups, most of whom were providers, either in the public (governmental) or the private (for-profit or non-governmental) sector. Providers (...) Review: provider practice and user behavior interventions to improve prompt and effective treatment of malaria: do we know what works? Review: provider practice and user behavior interventions to improve prompt and effective treatment of malaria: do we know what works? Review: provider practice and user behavior interventions to improve prompt and effective treatment of malaria: do we know what works? Smith L A, Jones C, Meek S, Webster J CRD summary The authors concluded that there was little

2009 DARE.

137. Summary of recommendations on malaria issues in special hosts (Full text)

chemoprophylaxis. Chemoprophylaxis for pregnant and breastfeeding women and for children requires careful consideration in the context of the pregnancy trimester, the age or size of the infant/child as well as their glucose-6-phosphate dehydrogenase (G6PD) status. Recommendations for long-term travellers, expatriates and people visiting friends and relatives (VFRs) do not differ markedly from those for short-term travellers. Some underlying medical conditions may make individuals more vulnerable to malaria (...) Summary of recommendations on malaria issues in special hosts On behalf of the Public Health Agency of Canada, the Committee to Advise on Tropical Medicine and Travel (CATMAT) developed the Canadian Recommendations for the Prevention and Treatment of Malaria Among International Travellers for Canadian health care providers who are preparing patients for travel to malaria-endemic areas and treating travellers who have returned ill.To provide guidelines on malaria issues related to special

2014 Canada Communicable Disease Report

138. Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. (Full text)

Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. A 23-year-old healthy male volunteer took part in a clinical trial in which the volunteer took chloroquine chemoprophylaxis and received three intradermal doses at four-week intervals of aseptic, purified Plasmodium falciparum sporozoites to induce protective immunity against malaria. Fifty-nine days after the last administration of sporozoites and 32 days after the last dose of chloroquine (...) the volunteer underwent controlled human malaria infection (CHMI) by the bites of five P. falciparum-infected mosquitoes. Eleven days post-CHMI a thick blood smear was positive (6 P. falciparum/μL blood) and treatment was initiated with atovaquone/proguanil (Malarone®). On the second day of treatment, day 12 post-CHMI, troponin T, a marker for cardiac tissue damage, began to rise above normal, and reached a maximum of 1,115 ng/L (upper range of normal = 14 ng/L) on day 16 post-CHMI. The volunteer had one

2014 Malaria journal

139. Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: a randomized, controlled trial in Mozambique. (Full text)

Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: a randomized, controlled trial in Mozambique. The impact of the age of first Plasmodium falciparum infection on the rate of acquisition of immunity to malaria and on the immune correlates of protection has proven difficult to elucidate. A randomized, double-blind, placebo-controlled trial using monthly chemoprophylaxis with sulphadoxine-pyrimethamine plus artesunate was conducted to modify (...) of infected erythrocytes by flow cytometry. Factors affecting antibody responses in relation to chemoprophylaxis and malaria incidence were evaluated.Generally, antibody responses did not vary significantly between exposure groups except for levels of IgM to EBA-175, and seropositivity of IgG1 and IgG3 to MSP-1(19). Previous and current malaria infections were strongly associated with increased IgG against MSP-1(19), EBA-175 and AMA-1 (p < 0.0001). After adjusting for exposure, only higher levels of anti

2014 Malaria journal Controlled trial quality: predicted high

140. The distribution of incubation and relapse times in experimental human infections with the malaria parasite Plasmodium vivax. (Full text)

parametric distributions that can be readily implemented for the incubation period and time-to-first relapse in P. vivax infections, including global subregions by parasite source. These analyses were complemented with a pooled analysis of observational human infection data with infections that included malaria chemoprophylaxis and long-latencies. The epidemiological impact of these distributional assumptions was explored using stochastic epidemic simulations at a fixed reproductive number while varying (...) The distribution of incubation and relapse times in experimental human infections with the malaria parasite Plasmodium vivax. The distributions of incubation and relapse periods are key components of infectious disease models for the malaria parasite Plasmodium vivax; however, detailed distributions based upon experimental data are lacking.Using a range of historical, experimental mosquito-transmitted human infections, Bayesian estimation with non-informative priors was used to determine

2014 BMC Infectious Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>